Imaging of Prostate-Specific Membrane Antigen Using [18F]DCFPyL

Steven P. Rowe; Michael A. Gorin; Martin G. Pomper

doi:10.1016/j.cpet.2017.02.006

Imaging of Prostate-Specific Membrane Antigen Using [¹⁸F]DCFPyL

Steven P. Rowe, Michael A. Gorin, Martin G. Pomper

School of Medicine

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Prostate-specific membrane antigen (PSMA) has been explored as a target for molecular imaging of prostate cancer and other malignancies that express PSMA in their tumor-associated neovasculature. Although several PSMA-targeted radiotracers labeled with a variety of radionuclides have been reported, positron-emitting radiotracers labeled with ¹⁸F are of particular interest. One such compound, the small molecule PSMA inhibitor [¹⁸F]DCFPyL, has demonstrated initial success. This article reviews the literature on this radiotracer, including radiosynthetic approaches to the molecule, data that are available from preclinical experiments, and evidence to date of the clinical utility of this agent in prostate cancer and clear cell renal cell carcinoma.

Original language	English (US)
Pages (from-to)	289-296
Number of pages	8
Journal	PET Clinics
Volume	12
Issue number	3
DOIs	https://doi.org/10.1016/j.cpet.2017.02.006
State	Published - Jul 2017

Keywords

DCFPyL
Prostate cancer
Radiopharmaceutical

ASJC Scopus subject areas

Radiation
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.cpet.2017.02.006

Cite this

@article{f9262358a4c54489959c185e568daab3,

title = "Imaging of Prostate-Specific Membrane Antigen Using [18F]DCFPyL",

abstract = "Prostate-specific membrane antigen (PSMA) has been explored as a target for molecular imaging of prostate cancer and other malignancies that express PSMA in their tumor-associated neovasculature. Although several PSMA-targeted radiotracers labeled with a variety of radionuclides have been reported, positron-emitting radiotracers labeled with 18F are of particular interest. One such compound, the small molecule PSMA inhibitor [18F]DCFPyL, has demonstrated initial success. This article reviews the literature on this radiotracer, including radiosynthetic approaches to the molecule, data that are available from preclinical experiments, and evidence to date of the clinical utility of this agent in prostate cancer and clear cell renal cell carcinoma.",

keywords = "DCFPyL, Prostate cancer, Radiopharmaceutical",

author = "Rowe, {Steven P.} and Gorin, {Michael A.} and Pomper, {Martin G.}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = jul,

doi = "10.1016/j.cpet.2017.02.006",

language = "English (US)",

volume = "12",

pages = "289--296",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Imaging of Prostate-Specific Membrane Antigen Using [18F]DCFPyL

AU - Rowe, Steven P.

AU - Gorin, Michael A.

AU - Pomper, Martin G.

PY - 2017/7

Y1 - 2017/7

N2 - Prostate-specific membrane antigen (PSMA) has been explored as a target for molecular imaging of prostate cancer and other malignancies that express PSMA in their tumor-associated neovasculature. Although several PSMA-targeted radiotracers labeled with a variety of radionuclides have been reported, positron-emitting radiotracers labeled with 18F are of particular interest. One such compound, the small molecule PSMA inhibitor [18F]DCFPyL, has demonstrated initial success. This article reviews the literature on this radiotracer, including radiosynthetic approaches to the molecule, data that are available from preclinical experiments, and evidence to date of the clinical utility of this agent in prostate cancer and clear cell renal cell carcinoma.

AB - Prostate-specific membrane antigen (PSMA) has been explored as a target for molecular imaging of prostate cancer and other malignancies that express PSMA in their tumor-associated neovasculature. Although several PSMA-targeted radiotracers labeled with a variety of radionuclides have been reported, positron-emitting radiotracers labeled with 18F are of particular interest. One such compound, the small molecule PSMA inhibitor [18F]DCFPyL, has demonstrated initial success. This article reviews the literature on this radiotracer, including radiosynthetic approaches to the molecule, data that are available from preclinical experiments, and evidence to date of the clinical utility of this agent in prostate cancer and clear cell renal cell carcinoma.

KW - DCFPyL

KW - Prostate cancer

KW - Radiopharmaceutical

UR - http://www.scopus.com/inward/record.url?scp=85016434708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016434708&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2017.02.006

DO - 10.1016/j.cpet.2017.02.006

M3 - Review article

C2 - 28576167

AN - SCOPUS:85016434708

SN - 1556-8598

VL - 12

SP - 289

EP - 296

JO - PET Clinics

JF - PET Clinics

IS - 3

ER -